Axcella Therapeutics, Inc.

Biotechnology valuations generally have been on the rise in recent months, relative to general stock market indices, but there still are a number of drug developers that are having trouble gaining tra

Non-alcoholic steatohepatitis is a hard therapeutic space to stand out in, but cash-poor Axcella Therapeutics, Inc. is trying to get attention from partners or financial backers with positive interi

The European Association for the Study of the Liver’s virtual International Liver Conference kicked off with largely incremental data in therapy areas like non-alcoholic steatohepatitis (NASH) and pri

While analysts were divided on whether there were broader implications for non-alcoholic steatohepatitis (NASH) R&D following the complete response letter that Intercept Pharmaceuticals Inc. reveale